These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27901050)

  • 1. The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.
    Malhab LJ; Descamps S; Delaval B; Xirodimas DP
    Sci Rep; 2016 Nov; 6():37775. PubMed ID: 27901050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.
    Lin JJ; Milhollen MA; Smith PG; Narayanan U; Dutta A
    Cancer Res; 2010 Dec; 70(24):10310-20. PubMed ID: 21159650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.
    Wang X; Zhang W; Yan Z; Liang Y; Li L; Yu X; Feng Y; Fu S; Zhang Y; Zhao H; Yu J; Jeong LS; Guo X; Jia L
    Oncotarget; 2016 Jun; 7(25):38380-38391. PubMed ID: 27224919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neural precursor cell expressed, developmentally downregulated 8‑activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis.
    Zheng W; Luo Z; Zhang J; Min P; Li W; Xu D; Zhang Z; Xiong P; Liang H; Liu J
    Mol Med Rep; 2017 May; 15(5):2795-2801. PubMed ID: 28447739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
    Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
    Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
    EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.
    Tong S; Si Y; Yu H; Zhang L; Xie P; Jiang W
    Sci Rep; 2017 Jul; 7(1):5599. PubMed ID: 28717191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.
    Brownell JE; Sintchak MD; Gavin JM; Liao H; Bruzzese FJ; Bump NJ; Soucy TA; Milhollen MA; Yang X; Burkhardt AL; Ma J; Loke HK; Lingaraj T; Wu D; Hamman KB; Spelman JJ; Cullis CA; Langston SP; Vyskocil S; Sells TB; Mallender WD; Visiers I; Li P; Claiborne CF; Rolfe M; Bolen JB; Dick LR
    Mol Cell; 2010 Jan; 37(1):102-11. PubMed ID: 20129059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
    Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
    Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
    Jia L; Li H; Sun Y
    Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of neddylation by MLN4924 improves neointimal hyperplasia and promotes apoptosis of vascular smooth muscle cells through p53 and p62.
    Ai TJ; Sun JY; Du LJ; Shi C; Li C; Sun XN; Liu Y; Li L; Xia Z; Jia L; Liu J; Duan SZ
    Cell Death Differ; 2018 Feb; 25(2):319-329. PubMed ID: 29027989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway.
    Bailly A; Perrin A; Bou Malhab LJ; Pion E; Larance M; Nagala M; Smith P; O'Donohue MF; Gleizes PE; Zomerdijk J; Lamond AI; Xirodimas DP
    Oncogene; 2016 Jan; 35(4):415-26. PubMed ID: 25867069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
    Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
    Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLN4924, a Protein Neddylation Inhibitor, Suppresses the Growth of Human Chondrosarcoma through Inhibiting Cell Proliferation and Inducing Endoplasmic Reticulum Stress-Related Apoptosis.
    Wu MH; Lee CY; Huang TJ; Huang KY; Tang CH; Liu SH; Kuo KL; Kuan FC; Lin WC; Shi CS
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30586948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).
    Sumi H; Inazuka M; Morimoto M; Hibino R; Hashimoto K; Ishikawa T; Kuida K; Smith PG; Yoshida S; Yabuki M
    Biochem Biophys Res Commun; 2016 Nov; 480(3):380-386. PubMed ID: 27771247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
    Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
    Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication.
    Jiang Y; Jia L
    Anticancer Agents Med Chem; 2015; 15(9):1127-33. PubMed ID: 25742093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overactivated neddylation pathway as a therapeutic target in lung cancer.
    Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
    J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.